Polyrizon Ltd.
PLRZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLRZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLRZ
Polyrizon Ltd. (PLRZ) is a clinical-stage biopharmaceutical company developing Capture & Contain (C&C) intranasal drug delivery technologies, with no approved products or revenue to date and a need for substantial additional financing.
Key risk: Need for substantial additional funding
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$24.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Polyrizon Ltd. (PLRZ) is a clinical-stage biopharmaceutical company developing Capture & Contain (C&C) intranasal drug delivery technologies, with no approved products or revenue to date and a need for substantial additional financing.
- Polyrizon has never generated any revenue from product sales and has incurred significant losses since inception [sec · filed 2026-03-25].
- As of December 31, 2025, the company had cash and cash equivalents of $1.3 million and bank deposits of $16.2 million [sec · filed 2026-03-25].
- The company plans to begin its first clinical trial of its C&C product candidate in the third quarter of 2026 [sec · filed 2026-03-25].
- Polyrizon depends on enrollment of patients in upcoming clinical trials and faces risks common to early-stage drug development [sec · filed 2026-03-25].
- The company has financed operations primarily through equity sales, convertible loans, and grants from the Israeli Innovation Authority [sec · filed 2026-03-25].
What works
- Polyrizon's leadership team has an average of over 17 years of experience in life science companies, supported by a Scientific Advisory Board of world-renowned academics [sec · filed 2026-03-25].
- The company believes its multiple product candidates validating its technologies give it a distinct advantage in the marketplace [sec · filed 2026-03-25].
What to weigh
- Polyrizon has never generated revenue from product sales and expects to continue incurring significant losses for the foreseeable future [sec · filed 2026-03-25].
- The company will require significant additional financing to fund operations, and such funding may not be available on acceptable terms or at all [sec · filed 2026-03-25].
- Success in preclinical studies does not ensure later clinical trial success, and the company faces numerous risks including failed trials, safety issues, and regulatory challenges [sec · filed 2026-03-25].
- If Polyrizon is unable to obtain funding, it may be required to curtail, delay, or discontinue its research, development, or manufacturing programs [sec · filed 2026-03-25].
From the filings
Quoted directly from source documents.
Polyrizon has never generated revenue from product sales and expects continued losses.
“We have never generated any revenue from product candidates sales and may never be profitable.”
SEC filings · March 25, 2026
Cash position as of December 31, 2025.
“As of December 31, 2025, we had cash, cash equivalents of $1.3 million and bank deposits of $16.2 million.”
SEC filings · March 25, 2026
Planned start of first clinical trial.
“Begin our planned clinical trial of our C&C product candidates in the third quarter of 2026;”
SEC filings · March 25, 2026
Dependence on patient enrollment and clinical trial success.
“We depend on enrollment of patients in our upcoming clini”
SEC filings · March 25, 2026
Risks & what to watch (4)›
Key risks
- Need for substantial additional funding — Polyrizon expects to need significant additional financing, which may not be available on acceptable terms, potentially forcing curtailment of operations [sec · filed 2026-03-25].
- No revenue and history of losses — The company has never generated revenue from product sales and anticipates continued losses for the foreseeable future [sec · filed 2026-03-25].
- Clinical and regulatory uncertainty — Success in preclinical studies does not guarantee clinical trial success; the company faces risks of failed trials, safety issues, and regulatory delays [sec · filed 2026-03-25].
- Dependence on patient enrollment — Polyrizon's clinical trials depend on timely enrollment of patients, which may be difficult and could delay development [sec · filed 2026-03-25].
What to watch
- Initiation of the planned clinical trial for the C&C product candidate in Q3 2026 [sec · filed 2026-03-25].
- Ability to secure additional financing through equity, debt, or collaborations [sec · filed 2026-03-25].
- Progress in preclinical studies and any regulatory feedback from the FDA or EU Notified Bodies [sec · filed 2026-03-25].
Sources: SEC filings · Generated August 22, 2026 · How we verify sources →
Run Polyrizon Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Polyrizon Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 0.02
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 6 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$117K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 10,149 | $117K |
| citigroup inc | 1 | $12 |
Short Interest
as of Apr 21, 2026- % of float
- 2.2%
- Days to cover
- 1.2
- Shares short
- 34,582
- Daily short volume (Jun 9, 2026)
- 42.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLRZ short interestFrequently asked questions
What is the AI investment thesis for Polyrizon Ltd.?
Polyrizon Ltd. (PLRZ) is a clinical-stage biopharmaceutical company developing Capture & Contain (C&C) intranasal drug delivery technologies, with no approved products or revenue to date and a need for substantial additional financing.
Who is the CEO of Polyrizon Ltd.?
Mr. Tomer Izraeli is the chief executive officer of Polyrizon Ltd. (PLRZ).
Where is Polyrizon Ltd. headquartered?
Polyrizon Ltd. (PLRZ) is headquartered in Ra'anana, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.